Oncology outcomes
Can CHK1 blockade help BRCA-wild-type resistant ovarian cancer?
Open access · cc by · source: Europe PMC
In 49 heavily pretreated BRCAwt platinum-resistant HGSOC patients, prexasertib yielded ~29–33% ORR with manageable but frequent neutropenia before early trial stop.
How this study connects
Role on claims
Each row is a claim on a concept or method page where this paper supports, challenges, or qualifies the statement. Roles are hand-checked — not a model guess.
Not yet placed on a claim. This paper has study layers, but no concept page yet cites it as support, challenge, or qualifier.
Study at a glance
- Design
- Other — Open-label single-arm phase 2 basket cohorts (NCT02203513 cohorts 5–6) of IV prexasertib in BRCAwt platinum-resistant HGSOC; early sponsorship stop
- N
- N=49 · 24 biopsiable (cohort 5) + 25 non-biopsiable (cohort 6); 39 RECIST-evaluable
- Population
- Adults with BRCA wild-type platinum-resistant recurrent high-grade serous ovarian/related carcinoma
- Outcome
- ORR (primary), safety, PFS; exploratory replication-stress biomarkers
Structured fields used in claim comparison tables when every cited study has a complete layer.
Inspect source passages
Can CHK1 blockade help BRCA-wild-type resistant ovarian cancer?
These passages occur verbatim in the stored paper text. They support the points listed below; they do not verify every statement in the explanation.
Which patients were enrolled in this report?
49 heavily pretreated patients were enrolled (24 in cohort 5, 25 in cohort 6)
How did cohorts 5 and 6 differ?
biopsiable disease (cohort 5), or without biopsiable disease (cohort 6)
Key findings
Among 39 evaluable patients, ORR was 33.3% (cohort 5) and 28.6% (cohort 6); median PFS 4 vs 6 months; neutropenia in 85.7%. High POLA1/POLE/GINS3 transcripts tracked with PFS <6 months.
Methodology
An NCI open-label phase 2 enrolled cohorts with or without biopsiable disease, giving IV prexasertib 105 mg/m² every 2 weeks, assessing RECIST ORR, PFS, safety, and exploratory biopsy/blood biomarkers.
Limitations
Not a randomized comparative efficacy trial; early stop limited definitive primary-endpoint evaluation and generalizability.
Related papers in this topic
Same topic cluster — not a recommendation engine.
- miR-122 exosomes from fat stem cells sensitize HCC models to chemo
- A 22-gene classifier flags early metastasis after prostatectomy
- HDAC2 IHC tracks shorter PSA relapse in prostate cancer
- Does ovarian-cancer clone diversity predict death?
- Five integrated genomic subgroups track prostate-cancer relapse risk